AR048344A1 - Derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de kinasas - Google Patents
Derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de kinasasInfo
- Publication number
- AR048344A1 AR048344A1 ARP050101222A ARP050101222A AR048344A1 AR 048344 A1 AR048344 A1 AR 048344A1 AR P050101222 A ARP050101222 A AR P050101222A AR P050101222 A ARP050101222 A AR P050101222A AR 048344 A1 AR048344 A1 AR 048344A1
- Authority
- AR
- Argentina
- Prior art keywords
- radicals
- alkyl
- optionally substituted
- alkoxy
- chosen
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- -1 carboxy, hydroxyl Chemical group 0.000 abstract 22
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 150000003254 radicals Chemical class 0.000 abstract 12
- 125000003545 alkoxy group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
- 239000011707 mineral Substances 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 abstract 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 abstract 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente trata de derivados de la pirrolo(2,3-B)piridina, su preparacion y su utilizacion farmacéutica como inhibidores de kinasas. Estando estos productos en todas las formas isomeras y las sales, como medicamentos. Reivindicacion 1: Productos de formula (1) en la que: R representa H o se elige entre los valores de R2 y R3; R1 representa alquenilo o alquilo opcionalmente sustituido con -CO-NR7R8, -NR7R8, carboxi libre o esterificado, hidroxilo, alcoxi o un átomo de halogeno, R2 y R3, idénticos o diferentes, representan alquilo u -O-alquilo, opcionalmente sustituidos con -CO-NR7R8, -NR7R8, alcoxi, alcoxi-NR7R8, carboxi libre o esterificado o fenilo, él mismo opcionalmente sustituido; R4, R5 y R6, idénticos o diferentes, se eligen entre el átomo de H, los átomos de halogeno y los radicales ciano, amino, alcoxi o alquilo opcionalmente sustituido, pudiéndose elegir R4 además entre los valores siguientes: carboxaldehido -CH=O, formaldoxima -CH=N-OH y metilhidroxilamina -CH2NHOH; R7 y R8, idénticos o diferentes, se eligen entre H, alquilo, alquenilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, arilo y heteroarilo, monocíclicos o bicíclicos, estando todos estos radicales opcionalmente sustituidos, o bien R7 y R8 forman con el átomo de N al que están unidos un radical heterocíclico insaturado o bien parcial o totalmente saturado constituido por 3 a 10 eslabones y que comprende uno o varios heteroátomos elegidos entre O, S, N y NR14, estando este radical opcionalmente sustituido, estando todos los radicales anteriores alquilo, alquenilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, arilo y heteroarilo, monocíclicos o bicíclicos, así como el radical heterocíclico formado por R7 y R8 con el átomo de N al que están unidos, opcionalmente sustituidos con uno o varios radicales idénticos o diferentes, elegidos entre los átomos de halogeno y los radicales ciano, hidroxilo, alquilo, alcoxi, alquiltio, nitro, oxo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo-C(=O)-R9, -C(=O)-OR10, -N(R11)-C(=O)-R9, -N(R11)-C(=O)-OR10, -NR12R13, -C(=O)-NR12R13, -N(R11)-C(=O)-NR12R13, -S(O)n-R9, -N(R11)-S(O)n-R9, -S(O)n- NR12R13 y -N(R11)-S(O)n-NR12R13, n representa un numero entero de 0 a 2, estando estos ultimos radicales alquilo, alcoxi, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo, heteroarilalquilo ellos mismos opcionalmente sustituidos con uno o varios radicales idénticos o diferentes elegidos entre los átomos de halogeno y los radicales hidroxilo, alquilo, alcoxi, -NR12R13, carboxi libre o esterificado, CF3, nitro, ciano, fenilo y fenilalquilo, en los que el radical fenilo está él mismo opcionalmente sustituido con uno o varios radicales, idénticos o diferentes, elegidos entre los átomos de halogeno y los radicales hidroxilo, alquilo, alcoxi, carboxi libre o esterificado, CF3, nitro, ciano y piridilo; R9 representa alquilo, alquenilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, cicloalquilalquilo, heterocicloalquilalquilo, arilalquilo y heteroarilalquilo, estando todos estos radicales opcionalmente sustituidos; R10 representa los valores de R9 e H; R11 representa H o alquilo, opcionalmente sustituido; R12 y R13, idénticos o diferentes, representan H, acilo, alquilo, cicloalquilo, heterocicloalquilo, heteroarilo, SO2-heteroarilo, - SO2-alquilo, -SO2-fenilo, -CO-NH-fenilo y fenilo, estando estos radicales opcionalmente sustituidos, o bien R12 y R13 forman con el átomo de N al que están unidos un radical heterocíclico insaturado o bien parcial o totalmente saturado constituido por 3 a 10 eslabones y que comprende uno o varios heteroátomos elegidos entre O, S, N, y NR14, estando este radical opcionalmente sustituido; R14 representa los valores de R9 e H, acilo y carboxi libre y esterificado, estando los radicales R9, R10, R11, R12, R13 y R14 anteriores así como el radical cíclico que pueden formar R12 y R13 con el átomo de N al que están unidos opcionalmente sustituido con uno o varios radicales, idénticos o diferentes, elegidos entre los átomos de halogeno y los radicales alquilo, alquil-NH2, alquil-NHCO2alquilo, NH2, NHCO2alquilo, hidroxilo, alcoxi, hidroxialcoxi, carboxi libre o esterificado, CF3, SCF3, OCF3, OCHF2, SO2CF3, nitro, ciano, heterocicloalquilo, heteroarilo y fenilo, estando estos ultimos radicales cíclicos ellos mismos sustituidos con uno o varios radicales, idénticos o diferentes, elegidos entre los átomos de halogeno y los radicales alquilo, hidroxilo, alcoxi, carboxi libre o esterificado, CF3, SCF3, OCF3, OCHF2, SO2CF3, NH2, NHCO2alquilo, nitro y ciano, estando además todos los radicales arilo, heteroarilo y heterocicloalquilo anteriores opcionalmente sustituidos con un radical alquilenodioxi, siendo todos los radicales alquilo, alquenilo, alcoxi u -O-alquilo y alquiltio anteriores lineales o ramificados y comprendiendo como máximo 6 átomos de C, comprendiendo todos los radicales cicloalquilo anteriores como máximo 7 átomos de C, comprendiendo todos los radicales arilo, heteroarilo y heterocicloalquilo anteriores como máximo 10 átomos de C, estando dichos productos de formula (1) en todas las formas isomeras posibles racémicas, enantiomeras y diastereoisomeras, así como las sales de adicion con los ácidos minerales y orgánicos o con las bases minerales y orgánicas de dichos productos de formula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403354A FR2868422B1 (fr) | 2004-03-31 | 2004-03-31 | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048344A1 true AR048344A1 (es) | 2006-04-19 |
Family
ID=34946084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101222A AR048344A1 (es) | 2004-03-31 | 2005-03-30 | Derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de kinasas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7528147B2 (es) |
| EP (1) | EP1732546A2 (es) |
| JP (1) | JP4841543B2 (es) |
| KR (1) | KR20070014151A (es) |
| CN (1) | CN1950083A (es) |
| AR (1) | AR048344A1 (es) |
| AU (1) | AU2005229452A1 (es) |
| BR (1) | BRPI0509564A (es) |
| CA (1) | CA2558923A1 (es) |
| FR (1) | FR2868422B1 (es) |
| IL (1) | IL178310A0 (es) |
| MX (1) | MXPA06011161A (es) |
| TW (1) | TW200602344A (es) |
| UY (1) | UY28835A1 (es) |
| WO (1) | WO2005095399A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2868422B1 (fr) * | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| CN102070638A (zh) * | 2009-11-24 | 2011-05-25 | 上海药明康德新药开发有限公司 | 一种六氢-吡咯[3,4-c]吡咯-1-酮衍生物的制备方法 |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| SI3421468T1 (sl) * | 2013-11-13 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev replikacije virusov influence |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN112961159B (zh) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | 氨基嘧啶并吡唑/吡咯类衍生物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615873A (zh) * | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
| SE0102204D0 (sv) * | 2001-06-21 | 2001-06-21 | Leif Isaksson | New method |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2003000690A1 (en) * | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| FR2868422B1 (fr) * | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
-
2004
- 2004-03-31 FR FR0403354A patent/FR2868422B1/fr not_active Expired - Fee Related
-
2005
- 2005-03-30 EP EP05746934A patent/EP1732546A2/fr not_active Withdrawn
- 2005-03-30 KR KR1020067021575A patent/KR20070014151A/ko not_active Withdrawn
- 2005-03-30 BR BRPI0509564-6A patent/BRPI0509564A/pt not_active IP Right Cessation
- 2005-03-30 CA CA002558923A patent/CA2558923A1/fr not_active Abandoned
- 2005-03-30 MX MXPA06011161A patent/MXPA06011161A/es active IP Right Grant
- 2005-03-30 JP JP2007505596A patent/JP4841543B2/ja not_active Expired - Fee Related
- 2005-03-30 CN CNA2005800137910A patent/CN1950083A/zh active Pending
- 2005-03-30 TW TW094109913A patent/TW200602344A/zh unknown
- 2005-03-30 AR ARP050101222A patent/AR048344A1/es unknown
- 2005-03-30 WO PCT/FR2005/000773 patent/WO2005095399A2/fr not_active Ceased
- 2005-03-30 AU AU2005229452A patent/AU2005229452A1/en not_active Abandoned
- 2005-03-31 UY UY28835A patent/UY28835A1/es unknown
-
2006
- 2006-09-26 IL IL178310A patent/IL178310A0/en unknown
- 2006-09-29 US US11/541,051 patent/US7528147B2/en not_active Expired - Fee Related
-
2009
- 2009-03-24 US US12/410,135 patent/US7968566B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1950083A (zh) | 2007-04-18 |
| WO2005095399A2 (fr) | 2005-10-13 |
| CA2558923A1 (fr) | 2005-10-13 |
| BRPI0509564A (pt) | 2007-09-25 |
| UY28835A1 (es) | 2005-10-31 |
| WO2005095399A3 (fr) | 2006-06-01 |
| US20070093480A1 (en) | 2007-04-26 |
| AU2005229452A1 (en) | 2005-10-13 |
| FR2868422A1 (fr) | 2005-10-07 |
| IL178310A0 (en) | 2007-02-11 |
| US7968566B2 (en) | 2011-06-28 |
| TW200602344A (en) | 2006-01-16 |
| US7528147B2 (en) | 2009-05-05 |
| MXPA06011161A (es) | 2007-12-10 |
| EP1732546A2 (fr) | 2006-12-20 |
| KR20070014151A (ko) | 2007-01-31 |
| US20090233956A1 (en) | 2009-09-17 |
| JP2007530645A (ja) | 2007-11-01 |
| FR2868422B1 (fr) | 2006-07-14 |
| JP4841543B2 (ja) | 2011-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042936A1 (es) | Derivados de urea ciclica, su preparacion y su utilizacion farmaceutica como inhibidores de quinasas | |
| AR064729A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
| AR059085A1 (es) | Derivados azufrados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de quinasas | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| DOP2011000061A (es) | Compuestos de pirrol | |
| CO6400223A2 (es) | Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met | |
| PE20151764A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| ES2618703T3 (es) | Nuevos compuestos diazaspirocicloalcano y azaspirocicloalcano | |
| AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
| AR072518A1 (es) | Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met." | |
| AR059086A1 (es) | Derivados de urea ciclica su preparcion y su utilizacion farmaceutica como inhibidores de cinasas | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| NI201100020A (es) | NUEVOS DERIVADOS DE IMIDAZO[1,2-a] PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDOR DE MET. | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR063249A1 (es) | Derivados imidazolonas su preparacion como medicamentos, composiciones farmaceuticas, utilizacion como inhibidores de proteinas quinasas principalmente cdc7 | |
| NI201200002A (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb). | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| AR048344A1 (es) | Derivados de la pirrolo(2,3-b)piridina, su preparacion y su utilizacion farmaceutica como inhibidores de kinasas | |
| AR077446A1 (es) | Derivados de 2,3-dihidro-1h-imidazo(1,2-a) pirimidin-5-ona. su preparacion y su utilizacion farmaceutica | |
| AR036812A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |